SUBSCRIBE
SUBSCRIBE
News   Policy

RedPath Integrated Pathology, Inc. Awarded Medicare Reimbursement Coverage for PathFinderTG(R)

June 27, 2007 | 
1 min read
PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc. (“RedPath”) announced today that its genomic-based cancer diagnostic test, PathFinderTG®, has been approved by Highmark Medicare Services for reimbursement coverage.
Regulatory
MORE ON THIS TOPIC
FDA CDER director George Tidmarsh speaking in an FDA video
Regulatory
FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing woman starting down curved path with markers toward goal marked by flag
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
Regulatory
6 FDA Decisions To Watch For in Q4
September 29, 2025
 · 
9 min read
 · 
Tristan Manalac
Protection From Tariffs as an An umbrella that shields against import and export tariff taxes as a trade war storm increasing prices and straining supply chains as a business metaphor and a symbol for resilience in times of crisis and economic downturn.
Tariffs
Trump Sets 100% Pharma Tariff Deadline for October 1
September 26, 2025
 · 
2 min read
 · 
Tristan Manalac